Welcome to our dedicated page for LB PHARMACEUTICALS SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc reported that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His current term will end at the conclusion of that meeting, and he will continue serving on the Board and the Nominating and Corporate Governance Committee until then.
The company stated that Mr. Prensky’s decision was not due to any disagreement regarding operations, policies, or practices. After his Board service ends, he is expected to provide consulting services under an amended Transition, Separation, and Consulting Agreement, which allows his unvested stock options to continue vesting during the agreement term.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $23.78 per share and expire on March 5, 2036. They vest in three equal annual installments on March 6, 2027, March 6, 2028, and March 6, 2029, contingent on continued service. Following this grant, he holds 20,000 derivative securities directly.
LB PHARMACEUTICALS INC director Robert A. Lenz filed an initial ownership report on Form 3. This filing establishes his status as a director and formally records his position as an insider of the company, but it does not list any specific share transactions or derivative holdings.
LB Pharmaceuticals Inc appointed Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director, with a term running through the 2026 annual stockholder meeting, and named him to the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Dr. Lenz will receive a $40,000 annual board retainer, a $5,000 annual committee retainer, an initial option to purchase 20,000 shares vesting over three years, and annual options for 10,000 shares vesting by the next annual meeting.
The Board also promoted Gad Soffer to Chief Operating and Business Officer, with at-will employment, an annual base salary of $505,000, and eligibility for an annual bonus targeted at 40% of base salary. The company describes itself as a late-stage biopharmaceutical firm advancing lead candidate LB-102 for multiple neuropsychiatric indications.
LB Pharmaceuticals Inc. received an updated ownership report from RA Capital-affiliated investors. As of December 31, 2025, RA Capital Healthcare Fund, L.P. directly holds 2,208,604 shares of LB Pharmaceuticals common stock, representing 8.7% of the outstanding shares, based on 25,299,102 shares reported outstanding as of November 6, 2025.
RA Capital Management, L.P. acts as investment adviser to the fund, and Peter Kolchinsky and Rajeev Shah are controlling persons of the general partner entities. The filers state the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals and disclaim group status and beneficial ownership beyond what is required for Section 13(d) reporting.
Deep Track Capital and affiliates updated their ownership filing for LB Pharmaceuticals Inc. after participating in a private placement. Following the transaction, Deep Track Capital, LP and David Kroin report beneficial ownership of 3,352,804 shares of common stock, representing 11.7% of the company.
The issuer sold 3,306,571 common shares and pre-funded warrants to purchase up to 1,417,107 additional shares in the private placement. Deep Track Biotechnology Master Fund, Ltd holds 2,686,138 shares, or 9.4% of the class, and Deep Track Special Opportunities Fund, LP holds 666,666 shares, or 2.3%. The pre-funded warrants have a $0.0001 exercise price and are subject to a 9.99% beneficial ownership cap, so the reporting persons currently disclaim beneficial ownership of the underlying warrant shares. LB Pharmaceuticals agreed to register the resale of the purchased shares and warrant shares on a Form S-1 and to keep that registration effective under specified conditions.
LB Pharmaceuticals Inc. reported insider purchases of pre-funded warrants by Deep Track-affiliated funds. On February 6, 2026, Deep Track Biotechnology Master Fund, Ltd. acquired 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP acquired 93,925 pre-funded warrants, each at $21.1699 per warrant.
The pre-funded warrants are exercisable immediately at an exercise price of $0.0001 per share of common stock and do not expire. Their terms cap beneficial ownership at 9.99% of LB Pharmaceuticals’ outstanding common stock, preventing exercises that would put the holder and its affiliates above that threshold. Deep Track Capital, LP and David Kroin are reporting persons and state they may be deemed beneficial owners only to the extent of their pecuniary interests.
LB Pharmaceuticals Inc entered into a private placement financing, agreeing to sell 3,306,571 common shares and pre-funded warrants for up to 1,417,107 additional shares at prices around $21.17 per share, for estimated gross proceeds of about $100 million.
The company plans to use the net proceeds mainly to fund a Phase 2 trial of LB-102 as an adjunctive treatment for major depressive disorder, as well as for working capital and general corporate purposes. The multi-center, six-week trial is expected to enroll about 380 patients across roughly 50 sites in the U.S. and Europe.
LB Pharmaceuticals Inc. disclosed that BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in the company’s common stock. As of December 31, 2025, BlackRock reported beneficial ownership of 1,277,776 shares, representing 5.1% of LB Pharmaceuticals’ outstanding common stock.
BlackRock reported sole power to vote 1,262,836 shares and sole power to dispose of 1,277,776 shares, with no shared voting or dispositive power. The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 961,158 shares, representing 3.8 % of the outstanding common stock. It has sole power to vote 863,342 shares and sole power to dispose of 961,158 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals. Various persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.